Business Wire10.07.20
Cardiovascular Systems Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced the addition of independent board member Kelvin Womack.
Womack is currently the vice president for Diversity and Inclusion at St. Jude Children’s Research Hospital in Memphis, Tenn. Prior to this role, he served for 30 years as a consulting professional, primarily in the healthcare industry. His more recent roles include leading the federal healthcare consulting practices for Deloitte LLP and BearingPoint Inc.
“We are pleased to welcome Kelvin Womack as a new independent director to the CSI board,” said Scott Ward, chairman, president and CEO. “We believe that Kelvin’s comprehensive understanding of the healthcare industry, experience with federal and healthcare agencies, broad technological expertise, and status as a thought leader on diversity, inclusion and patient care will expand our Board’s understanding of critical issues facing our business in a rapidly changing environment and assist us as we seek to prevent unnecessary amputations and address disparities in the treatment of peripheral and coronary artery disease.”
CSI’s board routinely reviews its composition to ensure it includes the necessary skills, experience and perspective to direct its business objectives. With the addition of Womack, three independent directors have joined CSI’s board since July 2019. The CSI board is comprised of eight directors, seven of whom are independent.
Womack is currently the vice president for Diversity and Inclusion at St. Jude Children’s Research Hospital in Memphis, Tenn. Prior to this role, he served for 30 years as a consulting professional, primarily in the healthcare industry. His more recent roles include leading the federal healthcare consulting practices for Deloitte LLP and BearingPoint Inc.
“We are pleased to welcome Kelvin Womack as a new independent director to the CSI board,” said Scott Ward, chairman, president and CEO. “We believe that Kelvin’s comprehensive understanding of the healthcare industry, experience with federal and healthcare agencies, broad technological expertise, and status as a thought leader on diversity, inclusion and patient care will expand our Board’s understanding of critical issues facing our business in a rapidly changing environment and assist us as we seek to prevent unnecessary amputations and address disparities in the treatment of peripheral and coronary artery disease.”
CSI’s board routinely reviews its composition to ensure it includes the necessary skills, experience and perspective to direct its business objectives. With the addition of Womack, three independent directors have joined CSI’s board since July 2019. The CSI board is comprised of eight directors, seven of whom are independent.